



Revolutionize the diagnosis and intervention of autoimmune diseases using data-driven insights

Predicta Med is a healthcare technology company that provides an EMR integrated platform that assists providers with early detection and intervention of immune-related diseases.



Problem

Immune-related diseases are a major contributor to morbidity and mortality worldwide, and their prevalence is increasing. Given the complex mechanism of these diseases including vague and overlapping symptoms, it can take more than 4 years and more than 4 different provider visits to establish a formal diagnosis. The diagnostic process is further complicated and prolonged by the large volume of clinical notes from various providers and the prevalence of text duplication. These diagnostic delays often lead to prolonged patient suffering, hospitalizations and deteriorations, decreased quality of life, increased employee absenteeism as well as higher healthcare costs. This might also lead to prompting patients to seek alternative healthcare options.

Partners














Solution

Predicta Med's data-driven insights platform, PredictAl™, aims to improve the quality of care for patients with immune-related conditions and reduce healthcare costs by assisting health professionals to identify these diseases in advance of current standards. The EMR-integrated solution can assist providers in identifying individuals with undiagnosed immune-related conditions, creating a concise view of the most relevant clinical information based on their specialty and the patient's conditions, and enabling targeted interventions earlier in the course of the disease to help mitigate disease-related deterioration and complications. To date, the models have been trained and validated on more than 7M electronic medical patient records and 1.7M claims records.




Average duration to diagnose shortened significantly





Value proposition

For Primary Care Providers & Specialists:



Assist in identifying undiagnosed immune-related diseases

and initiate appropriate interventions prior to major health events and improve patient experience while delivering better outcomes



Reduce physician burden by decreasing chart review time and enabling more

efficient patient interactions



Assist in reducing complications and disease deterioration

due to undiagnosed immunerelated diseases, potentially reducing the overall cost of care



Empower clinicians in making data-driven decisions by identifying overlooked

information buried in notes



Financial Value

Revenue Generation

Overall, early detection of immune-related diseases can generate revenues for healthcare providers through increased patient volume, targeted diagnostic testing and procedures, specialized care and consultations, medication management, preventive care services, and involvement in research and clinical trials.

Cost Saving

Implementing PredictAl[™] can contribute to financial benefits for healthcare providers by reducing treatment costs and complications, improving patient outcomes, optimizing resource utilization, and reducing administrative burden.



About Us

- Guided by a strong medical advisory board of world renowned KOLs from large academic medical centers in Israel and the US
- Presence in northeastern US (marketing, sales, support) and in Israel (R&D)

- Founded in 2020, with the mission to revolutionize autoimmune diseases diagnosis and intervention using Al
- Company is led by seasoned Al and healthcare executives including veterans from leading companies
- Strong financial backing by leading VCs, CVCs and strategic healthcare investors

Leading Investors














Grants

Google Al Fund







predicta-med.com